$1.50+0.03 (+2.04%)
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases.
IN8bio, Inc. in the Healthcare sector is trading at $1.50. The stock is currently near its 52-week low of $1.17, remaining 22.7% below its 200-day moving average. Technical signals show neutral RSI of 64 and bullish MACD crossover, explaining why INAB maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include I...